CN1883638A - 治疗抑郁症的复方药物及其制备方法 - Google Patents
治疗抑郁症的复方药物及其制备方法 Download PDFInfo
- Publication number
- CN1883638A CN1883638A CN 200610083644 CN200610083644A CN1883638A CN 1883638 A CN1883638 A CN 1883638A CN 200610083644 CN200610083644 CN 200610083644 CN 200610083644 A CN200610083644 A CN 200610083644A CN 1883638 A CN1883638 A CN 1883638A
- Authority
- CN
- China
- Prior art keywords
- preparation
- radix
- group
- hour
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 71
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 140
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 138
- 239000000284 extract Substances 0.000 claims description 74
- 238000002360 preparation method Methods 0.000 claims description 71
- 239000007788 liquid Substances 0.000 claims description 41
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 37
- 239000000341 volatile oil Substances 0.000 claims description 34
- 238000000605 extraction Methods 0.000 claims description 31
- 238000001035 drying Methods 0.000 claims description 30
- 238000010438 heat treatment Methods 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000004064 recycling Methods 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 20
- 229950005162 benexate Drugs 0.000 claims description 14
- IAXUQWSLRKIRFR-SAABIXHNSA-N chembl2104696 Chemical compound C1C[C@@H](CNC(=N)N)CC[C@@H]1C(=O)OC1=CC=CC=C1C(=O)OCC1=CC=CC=C1 IAXUQWSLRKIRFR-SAABIXHNSA-N 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 208000020401 Depressive disease Diseases 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 10
- 238000004821 distillation Methods 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 10
- 238000010828 elution Methods 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 238000007654 immersion Methods 0.000 claims description 10
- 235000011477 liquorice Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 239000011347 resin Substances 0.000 claims description 10
- 229920005989 resin Polymers 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000001117 sulphuric acid Substances 0.000 claims description 10
- 235000011149 sulphuric acid Nutrition 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 10
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 9
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 9
- HZWXJJCSDBQVLF-UHFFFAOYSA-N acetoxysulfonic acid Chemical compound CC(=O)OS(O)(=O)=O HZWXJJCSDBQVLF-UHFFFAOYSA-N 0.000 claims description 8
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 abstract description 3
- 241000202726 Bupleurum Species 0.000 abstract description 2
- 241000234653 Cyperus Species 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 49
- 241000700159 Rattus Species 0.000 description 41
- 230000037396 body weight Effects 0.000 description 35
- 210000002784 stomach Anatomy 0.000 description 30
- 238000012360 testing method Methods 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 27
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 229960002464 fluoxetine Drugs 0.000 description 24
- 239000003643 water by type Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 229930006000 Sucrose Natural products 0.000 description 17
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 17
- 239000005720 sucrose Substances 0.000 description 17
- 230000037326 chronic stress Effects 0.000 description 16
- 230000036760 body temperature Effects 0.000 description 15
- 230000006399 behavior Effects 0.000 description 14
- 230000000994 depressogenic effect Effects 0.000 description 14
- 230000001430 anti-depressive effect Effects 0.000 description 13
- 238000012449 Kunming mouse Methods 0.000 description 12
- 230000036259 sexual stimuli Effects 0.000 description 12
- -1 butter Chemical compound 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 10
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- WHGYBXFWUBPSRW-UHFFFAOYSA-N Cycloheptaamylose Natural products O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 208000000114 Pain Threshold Diseases 0.000 description 8
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 8
- 229960004046 apomorphine Drugs 0.000 description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 8
- 239000003651 drinking water Substances 0.000 description 8
- 235000020188 drinking water Nutrition 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000037040 pain threshold Effects 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 7
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 7
- 238000007086 side reaction Methods 0.000 description 7
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 6
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 241000581650 Ivesia Species 0.000 description 6
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 6
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 6
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 230000002567 autonomic effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229960002275 pentobarbital sodium Drugs 0.000 description 6
- 229960003147 reserpine Drugs 0.000 description 6
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000015554 Dopamine receptor Human genes 0.000 description 5
- 108050004812 Dopamine receptor Proteins 0.000 description 5
- 239000006053 animal diet Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 230000000384 rearing effect Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000036592 analgesia Effects 0.000 description 4
- 210000000436 anus Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010003084 Areflexia Diseases 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical group C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- 229940087098 Oxidase inhibitor Drugs 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FABGTKBXHAEVKL-OWSLCNJRSA-N (8s,13s,14s,17s)-13-methyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3=CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FABGTKBXHAEVKL-OWSLCNJRSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010020802 Hypertensive crisis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 241000216843 Ursus arctos horribilis Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003663 metaraminol Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000000718 radiation-protective agent Substances 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008539 xiaoyao Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量/g·kg-1 | 动物数/只 | 自主活动次数/次 |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 640.00±144.960482.60±91.929*570.80±124.348534.30±114.598520.00±105.068*518.20±103.831* |
组别 | 剂量/g·kg-1 | 动物数/只 | 探洞次数/次 |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 69.50±14.08152.10±17.610*60.80±19.22854.30±18.53650.70±17.430*49.90±11.638** |
组别 | 剂量/g·kg-1 | 动物数/只 | 时间/s |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 88.53±15.79154.46±22.408**59.18±32.249*54.17±26.209**54.26±26.911**52.35±27.453** |
组别 | 剂量/g·kg-1 | 动物数/只 | 时间/s |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 181.30±28.589156.80±16.765*161.30±37.860142.20±40.135*154.90±24.768*151.60±26.475 |
组别 | 剂量/g·kg-1 | 动物数/只 | 睡眠数/只 |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 14237*3 |
组别 | 剂量/g·kg-1 | 动物数/只 | 睡眠潜伏期/s | 睡眠时间/s |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 2.798±0.4872.859±0.5282.895±0.4042.782±0.5072.620±0.3652.722±0.517 | 21.817±3.57428.367±9.06923.493±4.26925.015±6.235*25.534±4.22423.674±5.319 |
组别 | 剂量/g·kg-1 | 动物数 | 试验前体温/℃ | 试验后体温/℃ | 体温降低/℃ |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 38.213±0.569838.730±0.416538.820±0.456638.910±0.087638.660±0.337338.740±0.3438 | 32.753±0.858534.130±0.6750**33.790±0.7415*34.590±0.7172***34.035±0.6633**33.974±0.8171** | 5.460±0.95594.600±0.97525.030±0.85124.320±0.7068**4.625±0.84634.766±0.6381 |
组别 | 剂量/g·kg-1 | 动物数/只 | 实验前体温/℃ | 实验后体温/℃ | 体温降低/℃ |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 38.571±0.35638.450±0.46338.440±0.42738.430±0.41138.340±0.40338.380±0.352 | 37.082±0.70137.263±0.34037.150±0.59537.384±0.69337.010±0.53636.949±0.683 | 1.489±0.4501.187±0.4151.290±0.6141.046±0.433*1.330±0.5561.431±0.526 |
组别 | 剂量/g·kg-1 | 动物数/只 | 甩头次数/次 |
常水组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水0.00331.7414.677.333.67 | 101010101010 | 10.9±3.24715.4±5.082*12.3±4.90018.4+6.720**16.0±5.869*15.6±4.789* |
组别 | 剂量/g·kg-1 | 药前体重/g | 第一周体重/g | 第二周体重/g | 第三周体重/g |
常水组模型组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水等体积常水0.001650.877.333.671.83 | 208.60±17230208.97±17.605209.29±13.195206.01±12.624209.65±13.325209.63±12.567206.85±17.963 | 231.81±18.702229.18±16.469231.68±14.752222.98±12.468229.38±13.355231.37±11.717226.37±15.664 | 262.12±22.276248.63±19.906255.13±16.056251.66±8.652251.66±15.063254.72±14.645254.41±14.824 | 268.90±21.411251.21±18.885252.14±18.458248.19±9.623*257.48±14.095257.31±15.626258.12±13.821 |
组别 | 剂量/g·kg-1 | 第一周增重/g | 第二周增重/g | 第三周增重/g |
常水组模型组氟西汀组安乐片组大剂量组中剂量组小剂量组 | 等体积常水等体积常水0.001650.877.333.671.83 | 23.21±4.99120.21±7.36122.39±6.05816.97±3.268**19.73±6.34621.74±3.61719.52±5.807 | 30.31±8.12819.45±7.595**23.45±4.605*28.68±7.819Δ22.23±6.137*23.35±7.63428.04±7.344Δ | 6.78±5.7252.58±4.572-2.99±4.556***Δ-3.47±4.939***Δ5.87±3.5762.59±4.3003.71±6.824 |
组别 | 第1周 | 第2周 | 第3周 | |||
crossing | rearing | crossing | rearing | crossing | rearing | |
常水组模型组氟西汀安乐片大剂量中剂量小剂量 | 45.9±15.96843.0±12.58756.3±13.937Δ43.3±16.00050.1±17.84842.7±15.84746.0±14.659 | 10.3±4.32211.4±3.62714.8±3.584*Δ7.8±4.66210.1±4.4339.9±4.3329.6±4.274 | 18.5±6.32911.3±5.012*19.3±8.166Δ17.2±9.70517.1±5.840Δ16.0±5.497i 5.6±5.929 | 7.9±3.0715.3±2.9086.8±2.4406.3±3.3685.9±3.0355.1±3.3155.3±3.889 | 14.3±4.7157.6±4.195**15.0±7.303Δ14.8±6.356ΔΔ12.8±5.329Δ10.8±6.39110.0±6.018 | 3.8±2.8211.6±1.430*3.7±2.058Δ3.3±1.252Δ3.2±1.549Δ2.4±1.3502.6±1.713 |
组别 | 第1周糖水消耗 | 第2周糖水消耗 | 第3周糖水消耗 |
常水组模型组氟西汀安乐片大剂量中剂量小剂量 | 0.879±0.04320.847±0.06180.854±0.05280.855±0.04430.866±0.04540.850±0.04570.857±0.0528 | 0.895±0.04650.836±0.0746*0.904±0.0408Δ0.872±0.05400.913±0.0333ΔΔ0.908±0.0560Δ0.917±0.0654Δ | 0.752±0.07090.735±0.07660.869±0.0743**ΔΔ0.844±0.0684**ΔΔ0.782±0.07510.740±0.07690.865±0.120*Δ |
组别 | 剂量/g·kg-1 | NA/ng·g-1 | E/ng·g-1 | DA/ng·g-1 | 5-HT/ng·g-1 |
常水组模型组氟西汀安乐片大剂量中剂量小剂量 | 等体积常水等体积常水0.001650.877.333.671.83 | 5.213±0.7975.504±1.4845.421±0.8405.328±0.8045.892±0.535**6.190±0.533**5.970±1.553 | 1.552±0.5712.194±0.498*2.289±0.803*1.596±0.656Δ1.433±0.622ΔΔ1.808±0.6893.129±0.589***ΔΔ | 3.972±0.7652.656±0.701**3.746±0.986Δ3.768±0.747ΔΔ3.876±0.591ΔΔ3.856±0.798ΔΔ2.360±0.364*** | 2.131±0.5761.266±0.358**1.851±0.539Δ1.876±0.374ΔΔ1.813±0.298ΔΔ1.686±0.429Δ1.020±0.261*** |
组别 | 剂量/g·kg-1 | 动物数 | 成功回避次数 |
常水组氟西汀安乐片大剂量中剂量小剂量 | 等体积常水0.001650.877.333.671.83 | 888888 | 19.38±3.20421.50±2.61924.88±4.190*23.25±2.435*23.00±2.928*23.38±2.326* |
组别 | 剂量/g·kg-1 | 药前痛阈值/s | 药后30min/s | 药后60min/s | 药后90min/s |
常水氟西汀安乐片大剂量中剂量小剂量 | 等体积0.00331.7414.677.333.67 | 16.950±6.82116.774±5.17116.990±4.37916.467±5.43916.174±5.57116.896±6.144 | 13.889±6.46510.372±2.55513.814±7.02713.922±7.91515.261±8.91215.415±8.333 | 8.462±2.4689.301±4.38613.234±7.46411.470±5.96315.571±6.380**12.408±4.810* | 9.527±2.71713.246±5.04010.332±5.38214.980±7.200*14.594±4.467**9.251±2.808 |
组别 | 剂量/g·kg-1 | 动物数/只 | 扭体潜伏期/s | 扭体/次 | 镇痛率/% |
常水氟西汀安乐片 | 等体积0.00331.74 | 101010 | 332.10±106.776314.00±93.661336.30±124.032 | 20.80±7.45119.50±5.70117.50±8.797 | -6.2515.87 |
大剂量中剂量小剂量 | 14.677.333.67 | 101010 | 350.80±149.826480.50±133.279*436.00±132.933 | 16.90±5.84014.60±4.971*17.50±6.819 | 18.7529.8115.87 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100836447A CN100374134C (zh) | 2006-05-31 | 2006-05-31 | 治疗抑郁症的复方药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100836447A CN100374134C (zh) | 2006-05-31 | 2006-05-31 | 治疗抑郁症的复方药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1883638A true CN1883638A (zh) | 2006-12-27 |
CN100374134C CN100374134C (zh) | 2008-03-12 |
Family
ID=37582021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100836447A Expired - Fee Related CN100374134C (zh) | 2006-05-31 | 2006-05-31 | 治疗抑郁症的复方药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100374134C (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283910A (zh) * | 2011-08-05 | 2011-12-21 | 浙江省中医药研究院 | 抗抑郁作用的中药组合物及其制剂和制备方法 |
CN104435298A (zh) * | 2014-12-16 | 2015-03-25 | 裴妙荣 | 一种抗抑郁药物组合物 |
CN105168403A (zh) * | 2015-10-22 | 2015-12-23 | 任术德 | 一种舒心散 |
CN107951937A (zh) * | 2017-12-15 | 2018-04-24 | 苏州科技城医院 | 一种含有抗抑郁活性成分的口服药剂 |
CN109999122A (zh) * | 2019-04-25 | 2019-07-12 | 武汉圣润生物科技有限公司 | 一种改善抑郁症的大麻二酚保健酒及其制备方法 |
CN112089782A (zh) * | 2020-09-22 | 2020-12-18 | 上海市静安区中医医院 | 一种解郁中药药枕及其应用 |
CN112402572A (zh) * | 2020-11-05 | 2021-02-26 | 江西中医药大学 | 一种用于治疗抑郁症的药物组合物、制备方法及应用 |
CN112843202A (zh) * | 2021-02-07 | 2021-05-28 | 长春康彼达科技有限公司 | 一种具有抗抑郁作用的中药组合物及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292792C (zh) * | 2005-07-11 | 2007-01-03 | 杨永信 | 一种治疗抑郁症的中药药物 |
CN1768819A (zh) * | 2005-10-13 | 2006-05-10 | 叶明伟 | 治疗肝气郁结型脱发的中草药汤剂及制备方法 |
-
2006
- 2006-05-31 CN CNB2006100836447A patent/CN100374134C/zh not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102283910A (zh) * | 2011-08-05 | 2011-12-21 | 浙江省中医药研究院 | 抗抑郁作用的中药组合物及其制剂和制备方法 |
CN102283910B (zh) * | 2011-08-05 | 2013-04-17 | 浙江省中医药研究院 | 抗抑郁作用的中药组合物及其制剂和制备方法 |
CN104435298A (zh) * | 2014-12-16 | 2015-03-25 | 裴妙荣 | 一种抗抑郁药物组合物 |
CN105168403A (zh) * | 2015-10-22 | 2015-12-23 | 任术德 | 一种舒心散 |
CN107951937A (zh) * | 2017-12-15 | 2018-04-24 | 苏州科技城医院 | 一种含有抗抑郁活性成分的口服药剂 |
CN107951937B (zh) * | 2017-12-15 | 2021-04-02 | 苏州科技城医院 | 一种含有抗抑郁活性成分的口服药剂 |
CN109999122A (zh) * | 2019-04-25 | 2019-07-12 | 武汉圣润生物科技有限公司 | 一种改善抑郁症的大麻二酚保健酒及其制备方法 |
CN112089782A (zh) * | 2020-09-22 | 2020-12-18 | 上海市静安区中医医院 | 一种解郁中药药枕及其应用 |
CN112089782B (zh) * | 2020-09-22 | 2021-11-23 | 上海市静安区中医医院 | 一种解郁中药药枕及其应用 |
CN112402572A (zh) * | 2020-11-05 | 2021-02-26 | 江西中医药大学 | 一种用于治疗抑郁症的药物组合物、制备方法及应用 |
CN112402572B (zh) * | 2020-11-05 | 2022-08-16 | 江西中医药大学 | 一种用于治疗抑郁症的药物组合物、制备方法及应用 |
CN112843202A (zh) * | 2021-02-07 | 2021-05-28 | 长春康彼达科技有限公司 | 一种具有抗抑郁作用的中药组合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100374134C (zh) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1883638A (zh) | 治疗抑郁症的复方药物及其制备方法 | |
CN1895256A (zh) | 20(s)-原人参二醇在制备抗抑郁药物中的应用 | |
CN101032560A (zh) | 一种治疗睡眠障碍的中药组合物及制备方法 | |
CN1840166A (zh) | 温胆汤现代中药口服制剂及其生产方法 | |
CN1233387C (zh) | 一种治疗失眠症的中药复方制剂及其制备方法 | |
CN1285358C (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN1726929A (zh) | 一种治疗糖尿病的药物组合物 | |
CN1230161C (zh) | 柿叶提取物和它的制备方法及用途 | |
CN1927331A (zh) | 一种治疗慢性心力衰竭的中药制剂 | |
CN1813819A (zh) | 猴头子实体或猴头菌丝体及培养物提取物及制剂和制法 | |
CN1723936A (zh) | 一种抗抑郁症的中药及其制备方法 | |
CN1562113A (zh) | 一种治疗慢性盆腔炎的药物及其制备方法 | |
CN1660259A (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN1316960C (zh) | 复方蛤青滴丸及其制备方法 | |
CN1650895A (zh) | 从天然植物复方制剂中提取增强记忆制品药物的方法 | |
CN1066959C (zh) | 治疗脑积水的药物 | |
CN1186026C (zh) | 羟乙葛根素在制备治疗缺血性脑血管病新药中的应用 | |
CN1282470C (zh) | 一种抗抑郁中药及其制备方法 | |
CN1686514A (zh) | 治疗焦虑症、抑郁症的中药制剂及其生产方法 | |
CN1274318C (zh) | 治疗偏头痛的药物 | |
CN1277574C (zh) | 治疗更年期综合征及美容的组合物、制备方法及其用途 | |
CN1175828C (zh) | 一种抗房劳、抗衰老的药物组合物及其制备方法 | |
CN1651017A (zh) | 治疗颈椎病的药物组合物及制备方法 | |
CN1651030A (zh) | 一种抗病毒泡腾片及其制备方法 | |
CN1724036A (zh) | 促进体内分泌褪黑激素的药物以及相关中药组合物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG TAIYUAN CHINESE MEDICINE RESEARCH AND DEV Free format text: FORMER OWNER: ZHU HONGLONG Effective date: 20091225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Shandong high tech Zone in Tai'an City, Phoenix Road South Patentee after: Shandong Taiyuan Chinese medicine research and Development Co.,Ltd. Address before: Shandong Province, Qingdao City, Hongkong Road No. 316 Nonghaiyuan B20 Patentee before: Zhu Honglong |
|
ASS | Succession or assignment of patent right |
Owner name: QINGDAO YANGGUANG HAICHUAN PHARMACEUTICAL TECHNOLO Free format text: FORMER OWNER: SHANDONG TAIYUAN TRADITIONAL CHINESE MEDICINE R + D CO., LTD. Effective date: 20101122 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 271000 SOUTH SECTION OF FENGTIAN ROAD, HIGH-TECH. ZONE, TAIAN CITY, SHANDONG PROVINCE TO: 266071 B20, NONGHAIYUAN, NO. 316, XIANGGANG EAST ROAD, LAOSHAN DISTRICT, QINGDAO CITY, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101122 Address after: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee after: QINGDAO SUNSHINE HAICHUAN MEDICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Address before: 271000 Shandong high tech Zone in Tai'an City, Phoenix Road South Patentee before: Shandong Taiyuan Chinese medicine research and Development Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: QINGDAO HAICHUAN CENTER FOR INNOVATIVE BIOMEDICAL Free format text: FORMER OWNER: QINGDAO YANGGUANG HAICHUAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20130220 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20130220 Address after: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee after: QINGDAO HAICHUAN INNOVATIVE BIOLOGY NATURAL RES CT Address before: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee before: Qingdao Sunshine Haichuan Medical Technology Development Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOP Free format text: FORMER OWNER: QINGDAO HAICHUAN CENTER FOR INNOVATIVE BIOMEDICAL RESEARCH Effective date: 20131224 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266071 QINGDAO, SHANDONG PROVINCE TO: 130012 CHANGCHUN, JILIN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131224 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee after: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. Address before: Laoshan District of Shandong city of Qingdao province Hongkong 266071 Road No. 316 Nonghaiyuan B20 Patentee before: QINGDAO HAICHUAN INNOVATIVE BIOLOGY NATURAL RES CT |
|
ASS | Succession or assignment of patent right |
Owner name: JILIN CHANGBAISHAN PHARMACEUTICAL GROUP CO., LTD. Effective date: 20140303 |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140303 Address after: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee after: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. Patentee after: JILIN CHANGBAISHAN PHARMACEUTICAL GROUP Co.,Ltd. Address before: 130012 No. 2426 Qianjin Street, Changchun hi tech Development Zone, Jilin Patentee before: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080312 |